Lonza Group AG (LONN.SW)
Manufactures medicines and vaccines for pharmaceutical and biotech companies worldwide.
560.20+0.00%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago-2.1%
The outlook
Lonza Group trades at 560.2, positioned solidly above both its 50- and 200-day moving averages and about three-quarters of the way up from its 52-week low. Analysts lean bullish with an average rating of Buy, and the consensus price target sits roughly 22% above the current level. The stock trades at a trailing P/E of 36.1, reflecting a premium valuation relative to broader market averages.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 23 analysts
Price trendAbove its 50- & 200-day averages
52-week range77% of the way from its 52-week low to high
Price targetAvg target +22% vs current price
Analyst price target
~12-month · 23 analysts680.70average target+21.5% vs now
Now 560.20
Low 550.00High 835.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$39.13B
52-wk high
591.00
52-wk low
454.60
50-day avg
527.15
200-day avg
525.10
Trailing P/E
36.1